Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: A review of structure-activity relationships

Pharmazie

Volumn 64, Issue 12, 2009, Pages 771-795

  Azam, Faizul ^a   Ibn Rajab, I A ^a   Alruiad, A A ^a  

^a Misurata University   (Libyan Arab Jamahiriya)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 1,2,4 TRIAZOLO[1,5 A][1,3,5]TRIAZINE DERIVATIVE; 1,2,4 TRIAZOLO[1,5 A]PYRAZINE DERIVATIVE; 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE DERIVATIVE; 1,2,4 TRIAZOLO[4,3 A]QUINOXALIN 1 ONE DERIVATIVE; 1,8 NAPHTHYRIDINE DERIVATIVE; ADENOSINE A2A RECEPTOR ANTAGONIST; BENZOTHIAZOLE DERIVATIVE; DEAZA XANTHINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIDAZO[2,1 I]PURIN 2,4 DIONE DERIVATIVE; IMIDAZO[2,1 I]PURIN 5 ONE DERIVATIVE; INDENO[1,2 D]PYRIMIDINE DERIVATIVE; LEVODOPA; NON XANTHINE DERIVATIVE; OXAZOLO[2,3 F]PURINEDIONE DERIVATIVE; OXAZOLO[5,4 D]PYRIMIDINE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE ACETAMIDE DERIVATIVE; PYRIMIDO[2,1 F]PURINDIONE DERIVATIVE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; THIENO PYRIMIDINE DERIVATIVE; THIOXANTHINE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; HETEROCYCLIC COMPOUND;

DEPRESSION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; DYSKINESIA; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; SYNTHESIS;

ANIMALS; ANTIPARKINSON AGENTS; HETEROCYCLIC COMPOUNDS; HUMANS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 75749094842     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9632     Document Type: Review

References (215)

1. Abou-Sleiman PM, Muqit MMK, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219.
2. 2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res Bull 64: 155-164.
3. Alanine A, Flohr A, Miller AK, Norcross RD, Riemer K (2001) Benzothiazole derivatives. WO01097786.
4. 2A receptor antagonists. Bioorg Med Chem Lett 14: 817-821.
5. Alanine A, Flohr A, Miller AK, Norcross RD, Riemer K (2006) Benzothiazole derivatives with activity as adenosine receptor ligands. US20060003986A1.
6. Ali H, Miiller CE, Daly JW, Beaven MA (1991) Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors and cyclic AMP: evidence for inhibition of antigen binding to IgE. J Pharmacol Exp Ther 258: 954-962.
7. Allain H, Bentué-Ferrer D, Akwa Y (2008) Disease modifying drugs and Parkinson's disease. Prog Neurobiol 84: 25-39.
8. Andrews MJI, Edwards P, Chambers MS, Schmidt W, Clase JA, Bar G, Hirst KL, Macleod A (2009) Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases. US7501411.
9. Azam F (2009) Synthesis of some urea and thiourea derivatives of naphtha[1,2-d]thiazol-2-amine as anti-Parkinsonian agents that cause neuroprotection against haloperidol-induced oxidative stress in mice. Med Chem Res 18: 287-308.
10. Azam F, Alkskas IA, Ahmed MA (2009a) Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo [4,5-d] pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice. Eur J Med Chem 44: 3889-3897.
11. Azam F, Barodia SK, Anwer T, Alam MM(2009b) Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. J Enzyme Inhib Med Chem 24: 808-817.
12. Balo C, Lopez C, Brea JM, Fernández F, Caamaño O (2007) Synthesis and evaluation of adenosine antagonist activity of a series of [1,2,4]triazolo[1,5-c]quinazolines. Chem Pharm Bull 55: 372-375.
13. 2A receptors. Eur J Med Chem 44: 2122-2127.
14. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61: 293-296.
15. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 4: 2539-2544.
16. 2A adenosine receptor antagonists. Curr Med Chem 2: 707-722.
17. Baraldi PG, Cacciari B, Spalutto G, Villatoro MJP, Zocchi C, Dionisotti S, Ongini E (1996) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists. J Med Chem 39: 1164-1171.
18. 2A adenosine receptor antagonists. J Med Chem 41: 2126-2133.
19. 3 adenosine receptor antagonists. J Med Chem 42: 4473-4478.
20. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Moro S, Klotz KN, Leung E, Varani K, Gessi S, Merighi S, Borea PA (2000) Pyrazolo[4,3-e]-1,2,4,- triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: influence of the chain at N8 pyrazole nitrogen. J Med Chem 43: 4768-4780.
21. Baraldi PG, Cacciari B, Moro S, Spallato GP, Pastorin G, Ros TD, Klotz KN, Varani K, Gessi S, Borea PA (2002a) Synthesis, biological activity and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine derivatives as human A3 adenosine receptor antagonists. J Med Chem 45: 770-780.
22. 2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 45: 115-126.
23. 3 adenosine receptors antagonists. J Med Chem 46: 1229-1241.
24. 3 adenosine receptor antagonists. J Med Chem 48: 4697-4701.
25. 2A adenosine receptors. WO05097140A2.
26. 2A receptor antagonists. Br J Pharmacol 135: 1435-1442.
27. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184: 285-294.
28. 2A antagonists. J Neurosci 23: 5361-5369.
29. Bolcato C, Cusan C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Morizzo E, Moro S (2008) Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signal 4: 39-46.
30. 3 receptors. Bioorg Med Chem 13: 5330-5337.
31. 2A antagonist CSC is associated with an increase in striatal preprodynorphinmRNAexpression in 6-OHDA-lesioned rats. Synapse 59: 435-444.
32. Bruns RF, Daly JW, Snyder SH (1983) Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc Natl Acad Sci USA 80: 2077-2080.
33. 2A adenosine receptor antagonists. Curr Top Med Chem 3: 403-411.
34. Cacciari B, Bolcato C, Spalluto G, Klotz KN, Bacilieri M, Deflorian F, Moro S (2007) Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Acomplete structure-activity profile. Purinergic Signal 3: 183-193.
35. Camaioni E, Costanzi S, Vittori S, Volpini R, Klotz KN, Cristalli G (1998) New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg Med Chem 6: 523-533.
36. 2B. Eur J Med Chem 39: 879-887.
37. 2A receptor and their uses thereof. US20036664252B2.
38. Catarzi D, Colotta V, Varano F, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (2004) 1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists. Il Farmaco 59: 71-81.
39. 3 adenosine receptor antagonists. Bioorg Med Chem 13: 705-715.
40. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurode-generative diseases. J Med Chem 51: 347-370.
41. 2A adenosine receptors. Bioorg Med Chem 8: 2581-2590.
42. 2A and metabotropic glutamate mGLU5 receptors increase their efficacy in reversing parkinsonian deficits in rats. Neuropsychopharmacol 29: 1451-1461.
43. Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Lucacchini A (2003a) Synthesis and structure activity relationships of a new set of 1,2,4-Triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists. Bioorg Med Chem 11: 3541-3550.
44. 2A adenosine receptor antagonists. Bioorg Med Chem 11: 5509-5518.
45. 2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148: 47-54.
46. Crespo MI, Prat QM, Gual RS, Castro PLJC, Slee DH (2008) 2,6-Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists. US20080058356A1.
47. Crivori P, Cruciani G, Carrupt PA, Testa B (2000) Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43: 2204-2216.
48. Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 15: 269-299.
49. 2-adenosine receptors. J Med Chem 28: 487-492.
50. Daly JW, Padgett WL, Eger K (1988) 7-Deaza-9-phenyladenines. A new class of adenosine receptor antagonists. Biochem Pharmacol 37: 3749-3753.
51. Daly JW, Padgett WL, Shamim MT (1996) Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem 29: 1305-1308.
52. DauerW, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
53. 2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br J Pharmacol 112: 659-665.
54. 2A adenosine receptor antagonists. Tetrahedron Lett 49: 4633-4635.
55. 1 ligands: requirements for receptor affinity. Bioorg Med Chem 4: 923-924.
56. 2A receptor antagonists. Bioorg Med Chem Lett 15: 4809-4813.
57. Dowling JE, Yao G, Chang H, Peng H, Vessels J, Petter RC, Kumaravel G (2007) Triazolopyrazines and methods of making and using the same. US20070010520A1.
58. Drabczynska A, Schumacher B, Müller CE, Wojciechowska JK, Michalak B, Pȩkala E, Kononowicz KK (2003) Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. Eur J Med Chem 38: 397-402.
59. Drabczynska A, Müller CE, Schumacher B, Hinz S, Wojciechowska JK, Michalak B, P?ekala E, Kononowicz KK (2004) Tricyclic oxazolo[2,3-f] purinediones: potency as adenosine receptor ligands and anticonvulsants. Bioorg Med Chem 12: 4895-4908.
60. Durcan MJ, Morgan PF (1989) Evidence for adenosine A2 receptor involvement in the hypomobility effects of adenosine analogues in mice. Eur J Pharmacol 168: 285-290.
61. 2 affinity. J Med Chem 34: 1431-1435.
62. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17: 3-16.
63. 1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives. J Med Chem 43: 2814-2823.
64. Ferrarini PL, Betti L, Cavallini T, Giannaccini G, Lucacchini A, Manera C, Martinelli A, Ortore G, Saccomanni G, Tuccinardi T (2004) Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem 47: 3019-3031.
65. Ferre S, Fuxe K, von Euler G, Johansson B, Fredholm BB (1992) Adenosine - dopamine interactions in the brain. Neuroscience 51: 501-512.
66. Francis JE, Cash WD, Psychoyos S, Ghai G,Wenk P, Friedmann RC, Atkins C,Warren V, Fumess P, Hyun JL, Stone GA, Desai M,WilliamsM(1988) J Med Chem 31: 1014-1020.
67. Fredholm BB, Ijzerman, AP, Jacobson KA, Klotz KN, Linden J (2001) International union of Pharmacology. XXV. nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
68. 1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 26(2-3): 258-273.
69. 2A receptor antagonist ST153. Eur J Pharmacol 579: 149-152.
70. Gatta F, Giudice RMD, Borioni A, Borea AP, Dionisotti S, Ongini E (1993) Synthesis of imidazo[l,2-c]pyrazolo[4,3-elpyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4 triazolo[5,1-i]purines: new potent adenosine A receptor antagonists. Eur J Med Chem 28: 569-576.
71. 2A receptor antagonists. WO0102409A1.
72. Gillespie RJ, Lerpinier J (2002) Pyrrolo[2,3-d]pyrimidines and their use as purinergic receptor antagonists. WO02055084A1.
73. 2A-receptor antagonists. US6787541.
74. Gillespie RJ, Lerpiniere J, Gaur S (2006) Pyrazolo[3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists. US20060111373A1.
75. 2A receptor. Part 1: discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 18: 2916-2919.
76. 2A receptor. Part 2: design and synthesis of 4-arylthieno[3,2- d]pyrimidine derivatives. Bioorg Med Chem Lett 18: 2920-2923.
77. 2A receptor. Part 3: design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. BioorgMed Chem Lett 18: 2924-2929.
78. Gillespie RJ, Lerpiniere J, Gaur S, Bamford SJ, Stratton GC, Leonardi S, Weiss SM (2008d) Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists. US7405219.
79. 2A adenosine receptor antagonists. Eur J Med Chem 31: 59-63.
80. GubaW, NettekovenM, Pulmann B, Riemer C, Schmitt S (2004) Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities? Bioorg Med Chem Lett 14: 3307-3312.
81. Hamilton HW, Ortwine DF, Worth DF, Badger EW, Bristol JA, Bruns RF, Haleen SJ, Steffen RP (1985) Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application. J Med Chem 28: 1071-1079.
82. 2A receptors in the caudate-putamen of rats. Eur J Neurosci 14: 1287-93.
83. 3 adenosine receptor antagonists. J Med Chem 43: 4636-4646.
84. 2A adenosine receptor by positron emission tomography. Eur J Med Chem 40: 421-437.
85. 2A adenosine receptor antagonists for positron emission tomography (PET). Eur J Med Chem 41: 7-15.
86. 2A receptor. Eur J Pharmacol 268: 95-104.
87. Jacobson KA, Kirk KL, Padgett WL, and Daly JW (1986) A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dopropylxanthine. Mol Pharmacol 29: 126-133.
88. 2- adenosine receptors. Biochem Pharmacol 37: 3653-3661.
89. 1 adenosine receptors. J Med Chem 32: 1873-1879.
90. 2-selective adenosine receptor antagonists. J Med Chem 36: 1333-1342.
91. 2 adenosine antagonist in vitro and in vivo. FEBS Lett 323: 141-144.
92. Jacobson KA, Shi D, Gallo-Rodriguez C, Manning M Jr, Muller CE, Daly JW, Neumeyer JL, Kiriasis L and Pfleideter W (1993c) Effect of trifluoromethyl- and other substituents on activity of xanthines at adenosine receptors. J Med Chem 36: 2639-2644.
93. 2A antagonists to the treatment of Parkinson's disease: Concluding remarks. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 257-263.
94. Jenner P (2003) A2A antagonists as novel nondopaminergic therapy for motor dysfunction in PD. Neurology 61(Suppl 6): 32-38.
95. 3 receptor antagonists. Bioorg Med Chem 12: 613-623.
96. 2A receptors in normal and parkinsonian mice. J Neurosci 25: 10414-10419.
97. Kalgutkar AS, Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1: 91-142.
98. 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthenes. Bioorg Med Chem Lett 18: 1397-1401.
99. Kanda T, Jenner P (2000) Actions of adenosine antagonists in primate model of Parkinson's disease. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 211-227.
100. 2A receptor-mediated striatal expression of c-fos. Eur J Neurosci 18: 296-302.
101. 2A receptor antagonists: A novel approach to the treatment of Parkinson's disease. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 1-15.
102. Katsushima T, Nieves L,Wells JN (1990) Structure-activity relationships of 8-cycloalkyl-l,3-dipropylxanthines as antagonists of adenosine receptors. J Med Chem 33: 1906-1910.
103. 1 receptor antagonists. Bioorg Med Chem 14: 3654-3661.
104. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45: 2131-2138.
105. 3 receptor subtypes. J Med Chem 41: 2835-2845.
106. 2A adenosine antagonists. Bioorg Med Chem 15: 2119-2122.
107. Klotz KN, Kachler S, Lambertucci C,Vittori S,Volpini R, CristalliG(2003) 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn Schmiedebergs Arch Pharmacol 367: 629-634.
108. 2B receptors ligands. BioorgMed Chem 17: 2812-2822.
109. 2A receptor antagonists with improved drug like properties and in vivo efficacy. J Med Chem 52: 709-717.
110. 1 receptors. J Med Chem. 31: 745-751.
111. 2A adenosine receptors. Bioorg Med Chem Lett 15: 4604-4610.
112. Martínez A, Terán HG, Brea J, Ravina E, Loza MI, Cadavid MI, Sanz F, Vidal B, Segarra V, Sotelo E (2008) Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2′-furyl)-1,2,4-triazolo[1,5- a]quinoxalines. Bioorg Med Chem 16: 2103-2113.
113. 1 receptor subtype. Mol Pharmacol 31: 247-252.
114. 2A adenosine receptor antagonists. Bioorg Med Chem 14: 2697-2719.
115. (2A)) antagonists. Bioorg Med Chem Lett 15: 1333-1336.
116. 2A antagonists. Part 1. Bioorg Med Chem Lett 15: 3670-3674.
117. Matasi JJ, Caldwell JP, Tulshian D, Silverman LS, Neustadt BR (2006) Adenosine A2A receptor antagonists. US7041666.
118. 2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem. 48: 6887-6896.
119. Miyamoto K, Yamamoto Y, Kurita M, Sakai R, Konno K, Sanae F, Ohshima T, Takagi K, Hasegawa T, Iwasaki N, Kakiuchi M, Kato H (1993) Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position. J Med Chem 36: 1380-1386.
120. 2A and Trk receptors. J Neurosci 26: 9250-9263.
121. 2A antagonists with improved solubility and metabolic stability. Bioorg Med Chem Lett 18: 5402-5405.
122. Moorjani M, Zhang X, Chen Y, Lin E, Rueter JK, Gross RS, Lanier MC, Tellew JE, Williams JP, Lechner SM, Malany S, Santos M, Ekhlassi P, Palomino JCC, Crespo MI, M Prat, Gual S, Díaz JL, Saunders J, Slee DH(2008b) 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A2A antagonists with reduced hERG liability. Bioorg Med Chem Lett 18: 1269-1273.
123. 2A receptor antagonists. US20080242672A1.
124. 2A receptor antagonists. US20080242673A1.
125. 2A receptors: an overview Brain Res Rev 31: 65-82.
126. 2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 251: 21-25.
127. Müller CE, Hide I, Daly JW, Rothenhäusler K, Eger K (1990) 7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists. J Med Chem 33: 2822-2828.
128. Müller CE, Scior T (1993) Adenosine receptors and their modulators. Pharm Acta Helv 68: 77-111.
129. Muller CE, Shi D, ManningMJr, Daly JW (1993) Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. J Med Chem 36: 3341-3349.
130. 1-adenosine receptor antagonists. J Med Chem 39: 2482-2491.
131. Muller CE, Stein B (1996b) Adenosine receptor antagonists: structures and potential terapeutic applications. Curr Pharm Des 2: 501-530.
132. 2A-selective adenosine receptor antagonists. J Med Chem. 40: 4396-4405.
133. 2A-adenosine receptor antagonist. Arch Pharm Med Chem 330: 181-189.
134. 2A-selective adenosine receptor antagonists. Bioorg Med Chem 6: 707-719.
135. 2A adenosine receptor antagonists - future drugs for Parkinson's disease? Drugs Fut 25: 1043-52.
136. 3 adenosine receptor antagonists. J Med Chem 45: 3440-3450.
137. Muller CE (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 3: 445-462.
138. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2: 1-21.
139. 2A receptor antagonists. WO03048163 A1.
140. 2A receptor antagonists. US6630475.
141. 2A receptor antagonists. US6897216.
142. 2A receptor antagonists. US7078408.
143. 2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2, 4-triazolo[1,5-c]pyrimidines. BioorgMed Chem Lett 17: 1376-1380.
144. 2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 19: 967-971.
145. 2B receptor antagonists. Bioorg Med Chem 17: 3426-3432.
146. Nomoto M (2000) Neurobiology of adenosine receptors. Adenosine and its metabolites in movement disorders. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 245-255.
147. 2 antagonist, (E)-1,3-dipropyl-8-(3,4- dimethoxystyryl)-7-methylxanthine. J Med Chem 36: 3731-3733.
148. 2 receptor antagonist. Eur J Pharmacol 267: 335-341.
149. Nonaka H, Ichimura M (2000) Biochemical characterization of adenosine agonists and antagonists. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 77-105.
150. 3 receptor Ligands. J Med Chem 45: 3703-3708.
151. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB (1999) Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmied Arch Pharmacol 359: 7-10.
152. 2A receptor antagonists. Il Farmaco 56: 87-90.
153. Pastorin G, Bolcato C, Cacciari B, Kachler S, Klotz KN, Montopoli C, Moro S, Spalluto G (2005) Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists. Il Farmaco 60: 299-306.
154. 1 receptors, and 125I-azido-BW-A844U, a photoaffinity label. Mol Pharmacol 33: 585-591.
155. Peet NP, Lentz NL, Meng EC, Dudley MW, Ogden AML, Demeter DA, Weintraub HJR, Bey P (1990) A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. J Med Chem 33: 3127-3130.
156. Peet NP, Lentz NL, Dudley MW, Ogden AML, McCarty DR, Racke MM (1993) Xanthines with C 8 chiral substituents as potent and selective adenosine A1 antagonists. J Med Chem 36: 4015-4020.
157. 2A receptor antagonists. J Med Chem 47: 6218-6229.
158. 2A adenosine receptor antagonists. US20070173505A1.
159. 2A receptor antagonists. Bioorg Med Chem 11: 1299-1310.
160. 2A receptors for Parkinson's disease. Neurotherapeutics 6: 141-151.
161. 2A receptor antagonists: Actions on Parkinson's disease models. Eur J Pharmacol 512: 157-164.
162. 2A receptor antagonists. Life Sci 77: 3259-3267.
163. 1 receptor antagonists. J Med Chem 39: 4156-4161.
164. 2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 16: 8676-8684.
165. Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F, Lluis C, Franco R, Woods AS, Goldberg SR, Ferré S (2004) Adenosine receptormediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and Nmethyl-D-aspartate receptor stimulation. J Neurochem 91: 873-880.
166. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
167. 2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett 16: 5993-5997.
168. 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546: 82-87.
169. Sakai R, Konno K, Yamamoto Y, Sanae F, Takagi K, Hasegawa T, Iwasaki N, Kakiuchi M, Kato H, Miyamoto K (1992) Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem 35: 4039-4044.
170. 2 antagonism. Behav Brain Res 201: 216-222.
171. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK (1990) 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 33: 2240-2254.
172. 2A-selective adenosine receptor antagonists. J Med Chem 43: 440-448.
173. Schapira AHV, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Novère NL, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G (2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5: 845-854.
174. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29: 647-654.
175. Seale TW, Abla KA, Shamim MT, Carney JM, Daly JW (1988) 3,7-Dimethyl-1-propagylxanthine: a potent and selective in vivo antagonist of adenosine analogues. Life Sci 43: 1671-1684.
176. 2A receptor antagonists. BioorgMed Chem Lett 18: 4199-4203.
177. 2A receptor antagonists. Bioorg Med Chem Lett 18: 4204-4209.
178. ShamimMT,Ukena D, Padgett WL, Hong O, DalyJW(1988) 8-Aryl- and 8-cycloalkyl-l,3-dipropylxanthines: further potent and selective antagonists for Al-adenosine receptors. J Med Chem 31: 613-617.
179. ShamimMT,Ukena D, Padgett WL, DalyJW(1989) Effects of 8-phenyl and 8-cycloalkyl substitents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. J Med Chem 32: 1231-1237.
180. 1 antagonist with renal protective and diuretic activities. J Med Chem 34: 466-469.
181. 1 adenosine receptors. J Med Chem 35: 924-930.
182. Shimada J, Suzuki, F, Nonaka H, Ishii A, Ichikawa S (1992b) (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem 35: 2342-2345.
183. 2A antagonists with potent anti-cataleptic activity. Bio Med Chem Lett 7: 2349-2352.
184. Shimada J, Suzuki F (2000) Medicinal chemistry of adenosine receptors in brain and periphery. In: Kase H, Richardson PJ, Jenner P (ed.) Adenosine antagonists and Parkinson's disease, Academic Press, San Diego, pp. 31-48.
185. 2A antagonists. Bioorg Med Chem Lett 17: 1659-1662.
186. 2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents. J Med Chem 51: 1719-1729.
187. Slee D, Lanier M, Vong BG, Chen Y, Zhang X, Lin E, Moorjani M, Castro PLJC (2008b) Substituted Pyrimidines as Adenosine Receptor Antagonists. US20080275064A1.
188. 2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships. J Med Chem. 51: 1730-1739.
189. 2A receptor antagonists with in vivo efficacy. J Med Chem 51: 400-406.
190. SongY, Coupar IM, IskanderMN(2001) Structural predictions of adenosine 2B antagonist affinity using molecular field analysis. Quant Struct-Act Relat 20: 23-30.
191. 2B adenosine receptor. Bioorg Med Chem 16: 2852-2869.
192. 2B adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem 16: 9780-9789.
193. 2A receptor antagonists. Drug Dev Res 52: 323-330.
194. 1-adenosine receptor antagonists. 9: 575-583.
195. 2A receptors. Prog Neurobiol 59: 355-396.
196. 2A receptor system using positron emission tomography. J Med Chem 43: 4359- 4362.
197. 2A receptor antagonist ST1535: Acute and subchronic studies in rats. Eur J Pharmacol 566: 94-102.
198. 1 receptor antagonists: further evidence for adenosine's anti mode of binding. Nucleosides Nucleotides 9: 275-291.
199. van Muijlwijk-Koezen JE, Timmerman H, Vollinga RC, Künzel JFD, de Groote M, Visser S, Ijzerman AP (2001) Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem 44: 749-762.
200. van Tilburg EW, van der Klein PAM, de Groote M, Beukers MW, IJzerman AP (2001) Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A1 receptor. Bioorg Med Chem Lett 11: 2017-2019.
201. van Veldhoven JPD, Chang LCW, Künzel JKVFD, Mulder-Krieger T, Struensee-Link R, Beukers MW, Brussee J, Ijzerman AP (2008) A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines. Bioorg Med Chem 16: 2741-2752.
202. Veber DF, Johnson SR, Cheng HY, Smith BR,WardKW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
203. 2A receptor antagonists: comparison of three core heterocycles. Bioorg Med Chem Lett 14: 4831-4834.
204. 2A receptor antagonists. J Med Chem 47: 4291-4299.
205. 2A receptor antagonists. Bioorg Med Chem Lett 14: 4835-4838.
206. 2A receptor antagonists. J Med Chem 48: 2009-2018.
207. 2A adenosine receptor antagonists. US20070010522A1.
208. Wardas J, Konieczny J, Lorenc-Koci E (2001) SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41: 160-171.
209. 2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61(Suppl 6): S101-S106.
210. 1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purine diones. Chem Med Chem 1: 891-902.
211. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105: 267-310.
212. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 15: 511-515.
213. 2A receptors antagonists: recent developments. Curr Med Chem 13: 3609-3625.
214. 2A receptor antagonists. Bioorg Med Chem Lett 18: 1778-1783.
215. 2A adenosine receptor antagonists for the treatment of parkinson's disease. J Med Chem 51: 7099-7110.